PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Futibatinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Biliary cancer; Brain cancer; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Glioma; Head and neck cancer; Mesothelioma; Neuroblastoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Skin cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms FOENIX-101; FOENIX-CCA2
- Sponsors Taiho Oncology
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 23 Sep 2023 This trial has been completed in Spain and Germany , according to European Clinical Trials Database record.
- 04 Jul 2023 According to a Taiho Oncology media release, John Bridgewater is the Investigator and Senior Author of the NEJM publication.